Microscope

THE STATE OF THE LIFE SCIENCES

The Life Sciences sector has continued to change rapidly as the world connects companies and technologies like never before. Throughout this change, the sector has been under many different pressures including economic forces, government regulations, and operational barriers. 

 

Regardless of the pressures, the life science field has fielded a number of changes in recent years. Whether it's the mega-mergers evident in the pharmaceutical sector, the increasing debate over payment policies of emerging treatments, or the evolving relationship between the public and private health sectors, successful companies must have a robust capacity to adapt to scientific, commercial, and operational changes. 

Moreover, with the inevitable digital revolution in life sciences, to continue to generate value, biopharma, healthcare IT, and medtech companies have been looking at implementing newer approaches such as data-driven technologies, automation, AI/ML and more to reduce drug development timelines, facilitate personalized treatment modalities, and create an improved patient experience.

 

CBE has worked with industry leaders such as Pfizer, Roche, and more to conduct research and provide strategy insights on pipeline analysis, data-based diagnostics, digital healthcare, direct-to-consumer healthcare, and more. 

S E C T O R S

  • PHARMACEUTICALS

    Pharmaceutical companies have recently undergone a wave of mega-mergers, particularly focusing on strengthening research pipelines in oncology and immunology. In addition, the industry has been shifting towards expanding the role of data to accelerate research and aid business decisions. Data based approaches have enabled better predictive models, more effective clinical trials, and targeted marketing.

  • BIOTECHNOLOGY

    As treatment platforms expand beyond traditional large-molecule therapies to fields such as monoclonal antibodies, bispecific antibodies, and nucleic acid therapies, the biotech field is filled with exciting potentials. In particular, genetics and CRISPR/Cas9 are becoming a central player for the future of the sector. Additionally, increasing computational research capabilities and enhanced data collection methods are revealing vast new insights from genomic, expression, and mutation datasets. 

  • MEDICAL DEVICES

    With a growing elderly population and increasing demand for noninvasive therapies, the potential for medical device innovation in traditional healthcare settings is promising. These prospects are bolstered by recent efforts by the Food & Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) to facilitate the process of medical device approval. Mobile health services are also projected to expand rapidly in the coming years. These products could revolutionize care coordination outside of healthcare facilities, provide digital therapies, and enhance user health on a day-to-day basis. 

  • DIGITAL HEALTH

    While big data has become increasingly adopted by other industries, the healthcare industry has been slow to adopt many digital solutions. In fact, electronic health records have only attained prominence in the past few years. Nonetheless, the implementation of data-driven health solutions can further personalize care and enhance medical insights throughout a patient’s treatment. While the path to success is riddled with challenges in data aggregation, patient privacy, data management, and regulations, the developments of these digital systems have vast potential to drive analytical healthcare innovations.

INDUSTRY REPORTS

B L O G  P O S T S

HARVARD UNDERGRADUATE CONSULTING ON BUSINESS AND THE ENVIRONMENT © 2020

  • Facebook
  • Instagram